HbA1c is outcome predictor in diabetic patients with sepsis

Diabetes Research and Clinical Practice

Volumn 77, Issue 1, 2007, Pages 120-125

  Gornik, Ivan ^a   Gornik, Olga ^b   Gašparović, Vladimir ^a  

^a KBC Zagreb   (Croatia)

^b UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

Diabetes; HbA1c; Prognosis; Sepsis

Indexed keywords

C REACTIVE PROTEIN; GLUCOSE; HEMOGLOBIN A1C;

ACCOUNTING; ADULT; APACHE; ARTICLE; CORRELATION ANALYSIS; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; LENGTH OF STAY; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIPLE REGRESSION; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL METHOD; OUTCOME ASSESSMENT; PREDICTION; PROSPECTIVE STUDY; SCORING SYSTEM; SEPSIS; SURVIVAL; UNIVERSITY HOSPITAL;

ADULT; AGED; APACHE; BLOOD GLUCOSE; C-REACTIVE PROTEIN; CROATIA; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HOSPITAL MORTALITY; HUMANS; LENGTH OF STAY; LOGISTIC MODELS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; SEPSIS;

EID: 34247161272     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2006.10.017     Document Type: Article

References (33)

1. Bertoni A.G., Saydah S., and Brancati F.L. Diabetes and the risk of infection-related mortality in the US. Diab. Care 24 (2001) 1044-1049
2. Falguera M., Pifarre R., Martin A., Sheikh A., and Moreno A. Etiology and outcome of community-acquired pneumonia in patients with diabetes mellitus. Chest 128 (2005) 3233-3239
3. Metan G., Zarakolu P., Cakir B., Hascelik G., and Uzun O. Clinical outcomes and therapeutic options of bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Int. J. Antimicrob. Agents 26 (2005) 254-257
4. Van den Berghe G.H. Role of intravenous insulin therapy in critically ill patients. Endocr. Pract. 10 Suppl. 2 (2004) 17-20
5. Van den Berghe G. How does blood glucose control with insulin save lives in intensive care?. J. Clin. Invest. 114 (2004) 1187-1195
6. Dellinger R.P., Carlet J.M., Masur H., Gerlach H., Calandra T., Cohen J., et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit. Care Med. 32 (2004) 858-873
7. Rahbar S. The discovery of glycated hemoglobin. Ann. N. Y. Acad. Sci. 1043 (2005) 9-19
8. Lapolla A., Traldi P., and Fedele D. Importance of measuring products of non-enzymatic glycation of proteins. Clin. Biochem. 38 (2005) 103-115
9. Ramasamy R., Vannucci S.J., Yan S.S., Herold K., Yan S.F., and Schmidt A.M. Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation. Glycobiology 15 (2005) 16R-28R
10. Genuth S., Alberti K.G., Bennett P., Buse J., Defronzo R., Kahn R., et al. Follow-up report on the diagnosis of diabetes mellitus. Diab. Care 26 (2003) 3160-3167
11. WHO Consultation. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1. Diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabet. Med. 15 (1998) 539
12. Levy M.M., Fink M.P., Marshall J.C., Abraham E., Angus D., Cook D., et al. 2001 International sepsis definition conference. Crit. Care Med. 31 (2003) 1250-1256
13. On behalf of the working group on sepsis-related problems of the european society of intensive care medicine. The SOFA (sepsis-related organ failure assessment) score to describe organ dysfunction/failure. Intensive Care Med. 22 (1996) 707-710
14. Knaus W.A., Draper E.A., Wagner D.P., and Zimmerman J.E. APACHE II: a severity of disease classification system. Crit. Care Med. 13 (1985) 818-829
15. Bessman A.N., and Sapico F.L. Infections in the diabetic patient: the role of immune dysfunction and pathogen virulence factors. J. Diab. Complications 6 (1992) 258-262
16. Turina M., Fry D.E., and Polk Jr. H.C. Acute hyperglycemia and the innate immune system: clinical, cellular, and molecular aspects. Crit. Care Med. 33 (2005) 1624-1633
17. Kjersem H., Hilsted J., Madsbad S., Wandall J.H., Johansen K.S., and Borregaard N. Polymorphonuclear leucocyte dysfunction during short term metabolic changes from normo- to hyperglycemia in type 1 (insulin dependent) diabetic patients. Infection 16 (1988) 215-221
18. Alba-Loureiro T.C., Hirabara S.M., Mendonca J.R., Curi R., and Pithon-Curi T.C. Diabetes causes marked changes in function and metabolism of rat neutrophils. J. Endocrinol. 188 (2006) 295-303
19. Coban E., Bostan F., and Ozdogan M. The mean platelet volume in subjects with impaired fasting glucose. Platelets 17 (2006) 67-69
20. Watala C., Golanski J., Pluta J., Boncler M., Rozalski M., Luzak B., et al. Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicylic acid (aspirin)-its relation to metabolic control. Thromb. Res. 113 (2004) 101-113
21. Rao A.K., Chouhan V., Chen X., Sun L., and Boden G. Activation of the tissue factor pathway of blood coagulation during prolonged hyperglycemia in young healthy men. Diabetes 48 (1999) 1156-1161
22. Stegenga M.E., van der Crabben S.N., Levi M., de Vos A.F., Tanck M.W., Sauerwein H.P., et al. Hyperglycemia stimulates coagulation, whereas hyperinsulinemia impairs fibrinolysis in healthy humans. Diabetes 55 (2006) 1807-1812
23. Yan S.F., Ramasamy R., Naka Y., and Schmidt A.M. Glycation, Inflammation, and RAGE: A Scaffold for the Macrovascular Complications of Diabetes and Beyond. Circ. Res. 93 (2003) 1159-1169
24. Schram M.T., Chaturvedi N., Schalkwijk C., Giorgino F., Ebeling P., Fuller J.H., et al. Vascular risk factors and markers of endothelial function as determinants of inflammatory markers in type 1 diabetes: the EURODIAB Prospective Complications Study. Diab. Care 26 (2003) 2165-2173
25. Tan K.C., Chow W.S., Tam S., Bucala R., and Betteridge J. Association between acute-phase reactants and advanced glycation end products in type 2 diabetes. Diab. Care 27 (2004) 223-228
26. Liliensiek B., Weigand M.A., Bierhaus A., Nicklas W., Kasper M., Hofer S., et al. Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J. Clin. Invest. 113 (2004) 1641-1650
27. Sampathkumar R., Balasubramanyam M., Rema M., Premanand C., and Mohan V. A novel advanced glycation index and its association with diabetes and microangiopathy. Metabolism 54 (2005) 1002-1007
28. Schleicher E.D., Wagner E., and Nerlich A.G. Increased accumulation of the glycoxidation product N(epsilon)-(carboxymethyl)lysine in human tissues in diabetes and aging. J. Clin. Invest. 99 (1997) 457-468
29. Kilhovd B.K., Berg T.J., Birkeland K.I., Thorsby P., and Hanssen K.F. Serum levels of advanced glycation end products are increased in patients with type 2 diabetes and coronary heart disease. Diab. Care 22 (1999) 1543-1548
30. Ono Y., Aoki S., Ohnishi K., Yasuda T., Kawano K., and Tsukada Y. Increased serum levels of advanced glycation end-products and diabetic complications. Diab. Res. Clin. Pract. 41 (1998) 131-137
31. Furth A.J. Glycated proteins in diabetes. Br. J. Biomed. Sci. 54 (1997) 192-200
32. Sharma C., Dalferes Jr. E.R., Radhakrishnamurthy B., Rosen E.L., and Berenson G.S. Nonenzymatic glycosylation of proteins and protease activities in granulation tissues in experimental diabetes. Inflammation 10 (1986) 403-411
33. Hadjadj S., Coisne D., Mauco G., Ragot S., Duengler F., Sosner P., et al. Prognostic value of admission plasma glucose and HbA1c in acute myocardial infarction. Diabet. Med. 21 (2004) 305-310